Estrella Immunopharma Inc./$ESLA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
- Ticker
- $ESLA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- EmeryVille, United States
- Website
- www.estrellabio.com
ESLA Metrics
BasicAdvanced
$35M
-
-$0.25
0.89
-
Price and volume
Market cap
$35M
Beta
0.89
52-week high
$2.43
52-week low
$0.24
Average daily volume
4.1M
Financial strength
Current ratio
0.197
Quick ratio
0.016
Profitability
Effective tax rate (TTM)
0.00%
Management effectiveness
Return on assets (TTM)
-251.86%
Return on equity (TTM)
148.05%
Valuation
Price to book
-4.6
Price to tangible book (TTM)
-4.6
Price to free cash flow (TTM)
-3.385
Free cash flow yield (TTM)
-29.54%
Free cash flow per share (TTM)
-0.235
Growth
Earnings per share change (TTM)
-24.93%
ESLA Financial Performance
Revenues and expenses
ESLA Earnings Performance
Company profitability
Upcoming events
No upcoming events
ESLA News
AllArticlesVideos
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Business Wire4 weeks ago
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.